foxo4-dri peptide senolytic 2023 study inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis Frontiers | Senolytic Peptide FOXO4-DRI

MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM

R.ApteU

Food and Drug Administration (FDA) announced that it will convene a public meeting of the Pharmacy Compounding Advisory Committee (PCAC) on July 23-24, 2026, to consider whether to recommend seven (7) peptide bulk drug substances for inclusion on the list of substances that may be used in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act

Distribution protocols accommodate the specific handling requirements of peptide research compounds and maintain temperature controls and packaging standards throughout the shipping process